Neuroblastoma differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Neuroblastoma}} | {{Neuroblastoma}} | ||
{{CMG}} | {{CMG}} | ||
==Differentiationg Neuroblastoma from other Diseases== | ==Differentiationg Neuroblastoma from other Diseases== | ||
Other [[tumors]] also have similar origins and show a wide pattern of differentiation ranging from [[benign]] [[ganglioneuroma]] to partially differentiated ganglioneuroblastoma to highly malignant neuroblastoma. | Other [[tumors]] also have similar origins and show a wide pattern of differentiation ranging from [[benign]] [[ganglioneuroma]] to partially differentiated ganglioneuroblastoma to highly malignant neuroblastoma. | ||
Revision as of 14:25, 17 August 2015
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma differential diagnosis |
|
Risk calculators and risk factors for Neuroblastoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Differentiationg Neuroblastoma from other Diseases
Other tumors also have similar origins and show a wide pattern of differentiation ranging from benign ganglioneuroma to partially differentiated ganglioneuroblastoma to highly malignant neuroblastoma.
The diagnosis is usually confirmed by a surgical pathologist, taking into account the clinical presentation, microscopic findings, and other laboratory tests. On microscopy, the tumor cells are typically described as small, round and blue, and rosette patterns (Homer-Wright pseudo-rosettes) may be seen. A variety of immunohistochemical stains are used by pathologists to distinguish neuroblastomas from histological mimics, such as rhabdomyosarcoma, Ewing's sarcoma, lymphoma and Wilms' tumor. The N-myc amplification is characteristic, and sometimes electron microscopy is also required. In February 2007, Althea Technologies announced the development of a molecular diagnostic capable of clearly differentiating various types of childhood cancers, developed in cooperation with the U.S. National Cancer Institute (NCI).[1]
References
- ↑ "Althea Technologies Announces the Development of a Diagnostic Capable of Differentiating Multiple Forms of Childhood Cancer", press release, February 20, 2007